Valanx BiotechVALANX Biotech has raised €3 million in a Series A funding round to advance an antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer. The developments are currently still at the preclinical stage.
Tag Archive for: Toxin
International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - sPositive signals from a partnership with Takeda are allowing Heidelberg Pharma to push the setback from a milestone payment not received as planned from Telix somewhat into the background. Nevertheless, the company has been strongly shaken and is now hoping for calmer waters in order to drive its clinical development forward with greater focus.
Tubulis GmbHMunich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.